Multimodal approaches to high-risk prostate cancer

  • A. Koupparis
  • M.E. Gleave

Abstract

Widespread use of testing for prostate-specific antigen (PSA) has led to a migration in the stage and grade of prostate cancer (PCa), with most men presenting with localized disease. However, 20%-35% of patients still present with high-risk disease (PSA > 20 ng/mL, biopsy Gleason score 8 10, or clinical stage T3). Despite advances in various treatment modalities, patients with high-risk disease have a significant chance of recurrence and death after surgery, often because of the presence of early occult metastasis at time of diagnosis. The optimal management of high-risk PCa remains controversial. The present article aims to discuss the traditional approaches and the more recent evolution toward multimodal therapies.

How to Cite
Koupparis, A., & Gleave, M. (1). Multimodal approaches to high-risk prostate cancer. Current Oncology, 17, S33-S37. https://doi.org/10.3747/co.v17i0.677